About
in vivo Gene Editing
Areas of Focus
Categories
Boston & New England
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
6
As Collaborator
0
Total Enrollment
213
By Phase
PHASE1/PHASE2: 1PHASE2: 2PHASE1: 2
By Status
RECRUITING: 2TERMINATED: 2COMPLETED: 2
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06876363Lead Sponsor
Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease
PHASE1/PHASE2Recruiting
15 participants
Started: Aug 5, 2025 · Completed: Dec 31, 2027
NCT06605378Lead Sponsor
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
N/ARecruiting
60 participants
Started: Nov 18, 2024 · Completed: Dec 31, 2025
NCT05445128Lead Sponsor
Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease
PHASE2Terminated
1 participants
Started: Jun 24, 2022 · Completed: Feb 2, 2023
NCT04762875Lead Sponsor
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
PHASE2Terminated
7 participants
Started: Jun 16, 2021 · Completed: Mar 14, 2022
NCT04154670Lead Sponsor
Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment
PHASE1Completed
23 participants
Started: Nov 7, 2019 · Completed: Mar 24, 2020
Locations (1)
Headquarters
Boston, MA, United States
Map
Loading map...